{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:11:49Z","timestamp":1786122709919,"version":"build-2736575974"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to develop and validate a green and sustainable hydrophilic interaction chromatography (HILIC) stability indicating assay for measuring the concentration of cisplatin and to evaluate its long-term stability at standardized rounded doses in polyolefin (POF) infusion bags at 25\u00b0C \u00b1 3\u00b0C, 60% \u00b1 5% relative humidity and protected from daylight. Physical stability, including colorimetry was periodically performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The HILIC with diode array detector method was fully validated and responds perfectly to degradation tests. Diluted cisplatin infusion solutions were aseptically prepared by further dilution of cisplatin stock solution with NaCl 0.9% in POF infusion bags (508 mL) at banded doses of 30 mg, 200 mg, and 400 mg. The POF bags were stored at 25\u00b0C in the dark. Physical and chemical stabilities were evaluated respectively through visual inspection, turbidity, particulate contamination, colorimetry measurements and through chromatographic assays, pH and osmolality monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>. The long-term stability of cisplatin was confirmed for at least 25 weeks at 25\u00b0C and in the dark. In addition, it was shown that a potential exposure of the cisplatin infusion bags in the natural light, the time to fall to 95% (90%) of the initial concentration would be estimated at eight (sixteen) minutes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A simple, accurate, and eco-friendly stability-indicating HILIC method was developed to determine cisplatin concentrations in dose-banding conditions associated for the first time with color variation investigation. This study supports a centralized production of cis-platine in accordance with the studied conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261475929","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:36:11Z","timestamp":1785944171000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long term stability study of cisplatin in polyolefin infusion bags in dose banding conditions using eco-friendly hydrophilic interaction chromatography and colorimetry methods"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-7780","authenticated-orcid":false,"given":"Yves Claude","family":"Guillaume","sequence":"first","affiliation":[{"name":"P\u00f4le Pharmacie, CHU de Besan\u00e7on"},{"name":"Universit\u00e9 Marie et Louis Pasteur, INSERM UMR1322 LINC, Laboratoire de Recherches Int\u00e9gratives en Neurosciences et Psychologie Cognitive, P\u00f4le Chimie Analytique Bioanalytique et Physique, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Lethier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, INSERM UMR1322 LINC, Laboratoire de Recherches Int\u00e9gratives en Neurosciences et Psychologie Cognitive, P\u00f4le Chimie Analytique Bioanalytique et Physique, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurad","family":"Cabut","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie, CHU de Besan\u00e7on"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Peudepiece","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie, CHU de Besan\u00e7on"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fagnoni-Legat","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie, CHU de Besan\u00e7on"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"ANDRE","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, INSERM UMR1322 LINC, Laboratoire de Recherches Int\u00e9gratives en Neurosciences et Psychologie Cognitive, P\u00f4le Chimie Analytique Bioanalytique et Physique, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.69424"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.357"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0048"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.18.1760"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000001047"},{"key":"e_1_3_2_7_2","unstructured":"Mylan Healthcare Limited. Summary of product characteristics for Cisplatin Mylan 1 mg\/mL concentrate for solution for infusion https:\/\/cdn.mylan-healthcare.com\/ie\/public\/spc\/ie-spc-clean_9.pdf."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02116167"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1992.tb01310.x"},{"key":"e_1_3_2_10_2","first-page":"11","article-title":"Physical and chemical stability of cisplatin infusions in PVC containers","volume":"4","author":"Sewell G","year":"2010","unstructured":"Sewell G. Physical and chemical stability of cisplatin infusions in PVC containers. Eur. J Oncol. Pharm 2010; 4: 11\u201313.","journal-title":"Eur. J Oncol. Pharm"},{"key":"e_1_3_2_11_2","first-page":"1500","article-title":"Characterization of cisplatin degradation as affected by pH and light","volume":"48","author":"Zieske PA","year":"1991","unstructured":"Zieske PA, Koberda M, Hines JL, et al. Characterization of cisplatin degradation as affected by pH and light. Am. J. Hosp. Pharm 1991; 48: 1500\u20131506.","journal-title":"Am. J. Hosp. Pharm"},{"key":"e_1_3_2_12_2","first-page":"956","article-title":"Current trends in HPLC column usage","volume":"27","author":"Majors R","year":"2009","unstructured":"Majors R. Current trends in HPLC column usage. LC-GC 2009; 27: 956\u2013972.","journal-title":"LC-GC"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1039\/b906215g"},{"key":"e_1_3_2_14_2","unstructured":"Search Results | CDC https:\/\/www.cdc.gov\/search\/index.html 2023 (accessed February 18 2025)."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/fermentation7040267"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30173567"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b16-00760"},{"key":"e_1_3_2_18_2","unstructured":"ASTM standard practice for computing the color of objects by using the CIE system; ASTM E308-08 West Conshohocken PA. 2012."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1533\/9781782423881.1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1533\/9780857099242.270"},{"key":"e_1_3_2_21_2","volume-title":"The international pharmacopoeia","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). The international pharmacopoeia. 8th ed. Elsevier, 2018, www. Webofpharma.com.","edition":"8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-016-0149-x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"e_1_3_2_24_2","unstructured":"SFPC (French Society of Clinical Pharmacy) and GERPAC (Evaluation and Research Group on Protection in Controlled Atmospher). SFPC GERPAC Methodological guidelines for stability studies of hospital pharmaceutical pre- parations Part I : Liquid preparations http:\/\/www.gerpac.eu\/IMG\/pdf\/ guide-stabilite-anglais.pdf (accessed 2 March 2019)."},{"key":"e_1_3_2_25_2","unstructured":"Pharmaceutical technical procedures 2.9.19: particulate contamination : sub-visible particles. In: European Pharmacopoeia. 9th ed. Strasbourg France : European Directorate for the Quality of Medicines and Health Care; 2019 : 360\u2013362."},{"key":"e_1_3_2_26_2","unstructured":"International Conference for Harmonisation. Harmonise tripartite guideline-stability testing of new drug substances and products Q1A(R2) step 4. www.ich.orghttps:\/\/www. ich.org\/fileadmin\/ Public-Web-Site \/ ICH-Products \/Guidelines\/Quality\/ Q1A R2\/Step4\/Q1AR2-Guideline.pdf (Published 2003 accessed 2 March 2019)."},{"key":"e_1_3_2_27_2","first-page":"101","article-title":"Validation des proc\u00e9dures analytiques quantitatives, Harmonisation des d\u00e9marches","volume":"13","author":"Hubert P","year":"2003","unstructured":"Hubert P, Boulanger B, Nguyen-Huu JJ, et al. Validation des proc\u00e9dures analytiques quantitatives, Harmonisation des d\u00e9marches. STP. Pharma. Pratiques 2003; 13: 101\u2013138.","journal-title":"STP. Pharma. Pratiques"},{"key":"e_1_3_2_28_2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures https:\/\/database.ich.org\/sites\/default\/files\/ICH-Q2%28R2%29-Guideline-2023-1130.pdf (2023 accessed 20 November 2024)."},{"key":"e_1_3_2_29_2","first-page":"10","article-title":"Methods for changing peak resolution in HPLC: advantages and limitations","volume":"31","author":"Shuster SA","year":"2013","unstructured":"Shuster SA, Johnson WL, De Stefano J, et al. Methods for changing peak resolution in HPLC: advantages and limitations. LC-GC Suppplements 2013; 31: 10\u201318.","journal-title":"LC-GC Suppplements"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cplett.2016.03.041"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87576-2"},{"key":"e_1_3_2_32_2","unstructured":"Monography 2.2.2. Degree of Coloration of Liquids: European Pharmacopoeia 10.5. (2021)."},{"key":"e_1_3_2_33_2","unstructured":"United States Pharmacopeia. USP <1061 > Color : Instrumental measurement USPNF 2021 Issue 2. (2021)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261475929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261475929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261475929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:24:49Z","timestamp":1786105489000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261475929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":32,"alternative-id":["10.1177\/10781552261475929"],"URL":"https:\/\/doi.org\/10.1177\/10781552261475929","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"10781552261475929"}}